Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$25.45|
|52 Week High||US$24.78|
|52 Week Low||US$55.22|
|1 Month Change||-11.32%|
|3 Month Change||-25.24%|
|1 Year Change||-41.18%|
|3 Year Change||6.75%|
|5 Year Change||n/a|
|Change since IPO||6.04%|
Recent News & Updates
Brokers Are Upgrading Their Views On Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) With These New Forecasts
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders will have a reason to smile today, with the analysts making...
|YMAB||US Biotechs||US Market|
Return vs Industry: YMAB underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: YMAB underperformed the US Market which returned 33.4% over the past year.
Stable Share Price: YMAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: YMAB's weekly volatility (8%) has been stable over the past year.
About the Company
|2015||125||Claus Møller San Pedro||https://www.ymabs.com|
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Y-mAbs Therapeutics Fundamentals Summary
|YMAB fundamental statistics|
Is YMAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|YMAB income statement (TTM)|
|Cost of Revenue||US$2.71m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.97|
|Net Profit Margin||-114.04%|
How did YMAB perform over the long term?See historical performance and comparison
Is Y-mAbs Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: YMAB ($25.45) is trading below our estimate of fair value ($320.46)
Significantly Below Fair Value: YMAB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: YMAB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: YMAB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate YMAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: YMAB is overvalued based on its PB Ratio (4.7x) compared to the US Biotechs industry average (2.9x).
How is Y-mAbs Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YMAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: YMAB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: YMAB's is expected to become profitable in the next 3 years.
Revenue vs Market: YMAB's revenue (48.5% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: YMAB's revenue (48.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: YMAB is forecast to be unprofitable in 3 years.
How has Y-mAbs Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: YMAB is currently unprofitable.
Growing Profit Margin: YMAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: YMAB is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.
Accelerating Growth: Unable to compare YMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: YMAB has a negative Return on Equity (-18.05%), as it is currently unprofitable.
How is Y-mAbs Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: YMAB's short term assets ($249.4M) exceed its short term liabilities ($21.0M).
Long Term Liabilities: YMAB's short term assets ($249.4M) exceed its long term liabilities ($4.2M).
Debt to Equity History and Analysis
Debt Level: YMAB is debt free.
Reducing Debt: YMAB has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: YMAB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if YMAB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Y-mAbs Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate YMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate YMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if YMAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if YMAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of YMAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Claus Møller San Pedro (59 yo)
Dr. Claus Juan Møller San Pedro, M.D., Ph.D. has been Chief Executive Officer of Y-mAbs Therapeutics, Inc. since June 2015 and serves as its Director. Dr. Møller was the founder of Azanta A/S, or Azanta, a...
CEO Compensation Analysis
Compensation vs Market: Claus's total compensation ($USD8.19M) is above average for companies of similar size in the US market ($USD2.25M).
Compensation vs Earnings: Claus's compensation has increased whilst the company is unprofitable.
Experienced Management: YMAB's management team is considered experienced (4.8 years average tenure).
Experienced Board: YMAB's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: YMAB insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.9%.
Y-mAbs Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Y-mAbs Therapeutics, Inc.
- Ticker: YMAB
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.109b
- Shares outstanding: 43.58m
- Website: https://www.ymabs.com
Number of Employees
- Y-mAbs Therapeutics, Inc.
- 230 Park Avenue
- Suite 3350
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 22:43|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.